PURPOSE: To evaluate the underexplored context of cystoscopy adherent versus non-adherent patients in the follow-up of urothelial high-risk non-muscle-invasive bladder cancer (NMIBC). METHODS: We performed a retrospective study (2005-2016) that evaluated patients´ demographical characteristics, histopathological data, recurrence, progression and cancer-specific mortality between adherent and non-adherents patients in the first 3 years of a proposed cystoscopy protocol. RESULTS: Among the 198 included patients, comparing cystoscopy non-adherent (n = 36, 18%) and adherent patients (n = 162, 82%), there was no demographic or histopathological differences; the rates of disease recurrence, progression and cancer-specific mortality were 15 (41.7%) versus 68 (42.2%), p = 0.58; 12 (33.3%) versus 28 (17.9%), p = 0.014 and 4 (11.1%) versus 19 (11.7%), p = 0.98, respectively. Cystoscopy non-adherence was associated with an inferior number of urinary cytology (p < 0.001) and 2.33 HR for cancer progression, p = 0.014, (95% CI 1.18-4.59). CONCLUSIONS: Non-adherence to follow-up cystoscopy in NMIBC is associated with more than twice progression risk. Future studies are needed to confirm our results and correlate cystoscopy non-adherence to other covariates.
PURPOSE: To evaluate the underexplored context of cystoscopy adherent versus non-adherent patients in the follow-up of urothelial high-risk non-muscle-invasive bladder cancer (NMIBC). METHODS: We performed a retrospective study (2005-2016) that evaluated patients´ demographical characteristics, histopathological data, recurrence, progression and cancer-specific mortality between adherent and non-adherents patients in the first 3 years of a proposed cystoscopy protocol. RESULTS: Among the 198 included patients, comparing cystoscopy non-adherent (n = 36, 18%) and adherent patients (n = 162, 82%), there was no demographic or histopathological differences; the rates of disease recurrence, progression and cancer-specific mortality were 15 (41.7%) versus 68 (42.2%), p = 0.58; 12 (33.3%) versus 28 (17.9%), p = 0.014 and 4 (11.1%) versus 19 (11.7%), p = 0.98, respectively. Cystoscopy non-adherence was associated with an inferior number of urinary cytology (p < 0.001) and 2.33 HR for cancer progression, p = 0.014, (95% CI 1.18-4.59). CONCLUSIONS: Non-adherence to follow-up cystoscopy in NMIBC is associated with more than twice progression risk. Future studies are needed to confirm our results and correlate cystoscopy non-adherence to other covariates.
Authors: Marko Babjuk; Andreas Böhle; Maximilian Burger; Otakar Capoun; Daniel Cohen; Eva M Compérat; Virginia Hernández; Eero Kaasinen; Joan Palou; Morgan Rouprêt; Bas W G van Rhijn; Shahrokh F Shariat; Viktor Soukup; Richard J Sylvester; Richard Zigeuner Journal: Eur Urol Date: 2016-06-17 Impact factor: 20.096
Authors: M Rouprêt; Y Neuzillet; A Masson-Lecomte; P Colin; E Compérat; F Dubosq; N Houédé; S Larré; G Pignot; P Puech; M Roumiguié; E Xylinas; A Méjean Journal: Prog Urol Date: 2016-11 Impact factor: 0.915
Authors: Ashish M Kamat; Paul K Hegarty; Jason R Gee; Peter E Clark; Robert S Svatek; Nicholas Hegarty; Shahrokh F Shariat; Evanguelos Xylinas; Bernd J Schmitz-Dräger; Yair Lotan; Lawrence C Jenkins; Michael Droller; Bas W van Rhijn; Pierre I Karakiewicz Journal: Eur Urol Date: 2012-10-04 Impact factor: 20.096
Authors: Sam S Chang; Stephen A Boorjian; Roger Chou; Peter E Clark; Siamak Daneshmand; Badrinath R Konety; Raj Pruthi; Diane Z Quale; Chad R Ritch; John D Seigne; Eila Curlee Skinner; Norm D Smith; James M McKiernan Journal: J Urol Date: 2016-06-16 Impact factor: 7.450
Authors: Faris Abushamma; Zain Khayyat; Aya Soroghle; Sa'ed H Zyoud; Ahmad Jaradat; Maha Akkawi; Hanood Aburass; Iyad K K Qaddumi; Razan Odeh; Husam Salameh; Salah Albuheissi Journal: Cancer Manag Res Date: 2021-03-31 Impact factor: 3.989
Authors: Leonardo Oliveira Reis; Luciana S B Dal Col; Diego M Capibaribe; Gustavo B de Mendonça; Fernandes Denardi; Athanase Billis Journal: Investig Clin Urol Date: 2022-01